Table 1.

The combinatory therapy of oncolytic vectors and CPIs for melanoma treatment.

OV	Checkpoint Inhibitor	Indication	Response Data	ClinicalTrials.gov ID
T-VEC	Ipilimumab	Melanoma	ORR 39% (comb.) vs. 18% (ipi alone)	NCT01740297
T-VEC	Pembrolizumab	Stage IIIB–IV melanoma	48% ORR	NCT02263508
T-VEC	Pembrolizumab	Stage III–IV melanoma	N/A	NCT02965716
HF-10	Ipilimumab	Melanoma	N/A	NCT031530085
HF-10	Ipilimumab	Melanoma	BORR 24% (at 24 weeks); median PFS 19 months; median OS 21.8 months	NCT02272855
HF-10	Nivolumab	Stage IIIB, IIIC, IVM1a melanoma	N/A	NCT03259425
CAVATAK	Ipilimumab	Uveal melanoma with liver metastasis	N/A	NCT03408587
CAVATAK	Pembrolizumab	Melanoma	N/A	NCT02565992
ONCOS-102	Pembrolizumab	Advanced or unresectable melanoma	N/A	NCT03003676